|
Jun 18
|
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
|
|
May 24
|
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
|
|
May 11
|
Analysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter Report
|
|
May 8
|
Immunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue Forecasts
|
|
May 8
|
Immunocore reports first quarter financial results and provides a business update
|
|
Apr 24
|
Immunocore announces upcoming presentation and posters at ASCO 2024
|
|
Apr 4
|
Immunocore to present at upcoming investor conferences
|
|
Mar 13
|
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
|
|
Mar 5
|
Immunocore presented two posters at CROI 2024
|
|
Jan 10
|
Best Momentum Stocks to Buy for January 10th
|
|
Jan 10
|
Should You Buy Immunocore Holdings PLC Sponsored ADR (IMCR) After Golden Cross?
|
|
Jan 5
|
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
|
|
Jan 3
|
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 31
|
An Intrinsic Calculation For Immunocore Holdings plc (NASDAQ:IMCR) Suggests It's 50% Undervalued
|
|
Dec 18
|
Immunocore Holdings PLC Sponsored ADR (IMCR) Upgraded to Buy: Here's What You Should Know
|
|
Nov 30
|
Levicept Appoints Eliot Forster as CEO
|
|
Nov 27
|
Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 75.55% to Reach the Level Wall Street Analysts Expect?
|
|
Jul 18
|
Immunocore Holdings (NASDAQ:IMCR) shareholders have earned a 41% return over the last year
|
|
Jun 7
|
With 45% stake, Immunocore Holdings plc (NASDAQ:IMCR) seems to have captured institutional investors' interest
|